Silexion Therapeutics Announces 1-for-9 Reverse Share Split
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:…
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:…
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ:…
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA (arimoclomol) for Treatment of Niemann-Pick Disease Type C
November 21, 2024 16:51 ET | Source: Zevra Therapeutics MIPLYFFA, the first…
BioXcel Therapeutics Announces Proposed Public Offering
November 21, 2024 16:47 ET | Source: BioXcel Therapeutics NEW HAVEN, Conn.,…
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
-- SRC recommended that the trial escalate to the next dose level…
Ben Austin, CFO and COO of SPR Therapeutics, Namedto Crains Cleveland Business 40 Under 40 List
CLEVELAND, Nov. 18, 2024 (GLOBE NEWSWIRE) -- For over 30 years, Crain’s…
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…